Optimi Health Corp.

Optimi Health Corp.

Optimi Health, ATMA Journey Centers To Proceed With Phase I Natural Psilocybin and MDMA Clinical Trial Application to Health Canada

Optimi Health Corp.Optimi aiming to become the first vertically integrated psychedelics firm to formulate and trial MDMA for healthy subjectsVANCOUVER, British Columbia, Sept. 22, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by Health Canada to produce and... Read More...

Optimi Health Signs First International Mushroom Supply Agreement with UK-based Avida Global

Optimi Health Corp.EU-GMP, operational, and service excellence to drive world-class sales pipelineFunctional MushroomsFunctional mushrooms grown at Optimi Health facility in Princeton, British Columbia.Lion's ManeLion's Mane mushrooms grown at Optimi Health facility in Princeton, British Columbia.Optimi LifeOptimi Life BundleVANCOUVER, Br... Read More...

Optimi Health Announces Canadian Retail and E-Commerce Distribution Agreements for Functional Mushroom Supplements and Appoints Chief Financial Officer to its Board of Directors

Optimi Health Corp.Deals position Optimi Life nutraceutical brand for international distributionOptimi LifeOptimi Life BundleOptimi LifeOptimi LifeOptimi LifeOptimi LifeVANCOUVER, British Columbia, Aug. 25, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by H... Read More...

Optimi Health Unveils Canada’s First Natural Therapeutic Psilocybin Product For Approved Patients

Optimi Health Corp.Blue Serenity (English)Optimi Health's, Blue Serenity psilocybin.Blue Serenity (English)Optimi Health's, Blue Serenity psilocybin.Blue Serenity Psilocybin PackagingOptimi Health's Blue Serenity psilocybin.Blue Serenity brings science and compassion together, will cement Thomas Hartle’s legacy as a Canadian psychedelic i... Read More...

Optimi Health To Launch Therapeutic Psilocybin Product In Partnership With Patient Advocate Thomas Hartle

VANCOUVER, British Columbia, Aug. 08, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company licensed by Health Canada to produce natural, scalable, and accessible psychedelic and functional mushrooms, as well as synthetic formulations for transformational human experie... Read More...

Optimi Health Finalizes Psilocybin Supply Agreement With Bloom Psychedelic Therapy And Research Centre

VANCOUVER, British Columbia, July 13, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company cultivating and synthesizing high quality psychedelics and natural functional and psilocybin mushroom strains for transformational human experiences, is pleased to announce that... Read More...

Optimi Health Initiates Agreement With SABI Mind For Therapeutic Supplies Of Psilocybin, MDMA

Optimi Health Corp.Optimi Health Cultivation and Analytical FacilitiesOptimi Health Cultivation and Analytical FacilitiesOptimi Health Fruiting RoomOptimi Health fruiting room being prepared for second grow.VANCOUVER, British Columbia, June 28, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), ... Read More...

Optimi Health Finalizes Partnership and Psilocybin Supply Agreement With ATMA Journey Centers

Optimi Health Corp.Strategic partnership will focus on improving regulatory outcomes in therapist training and safe supply of psilocybinVANCOUVER, British Columbia, June 08, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing natural, scalable, and accessib... Read More...

Open For Business: Optimi Completes First Grow of Psilocybin Mushrooms and Introduces Head of Cultivation

VANCOUVER, British Columbia, May 25, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human experiences, is pleased to announce an historical milestone in the Company’s road to ... Read More...

Optimi Health Applauds Health Canada’s Position on Drug Quality and Goods and Manufacturing Practices (GMP) for Psilocybin

VANCOUVER, British Columbia, May 09, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”) CEO, Bill Ciprick, issued a statement today in response to Health Canada’s May 6 Notice to Stakeholders “regarding the proposed use of psilocybin mushrooms in clinical trials, or as a drug accessed through the... Read More...

Optimi Health Opens Canada’s Largest GMP-Grade Licensed Psilocybin Cultivation Facility

VANCOUVER, British Columbia, April 28, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that it will be inaugurating its recently completed psilocybin cultivation facility with a grand opening event and reception for members of the media, investors and other stakeholders... Read More...

Optimi Health Begins Cultivation Of Natural Psilocybin For Use In Clinical Trials

Optimi Health Corp.VANCOUVER, British Columbia, March 18, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that it has commenced the cultivation of natural GMP-grade psilocybin mushrooms at its Princeton, British Columbia facility.“These mushrooms are an important milest... Read More...

Optimi Health Announces Investor Relations Agreement

VANCOUVER, British Columbia, March 08, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to announce it has entered into agreements with Kydde... Read More...

Optimi Health Upgrades Trading to the OTCQX Best Market

Optimi Health Corp.VANCOUVER, British Columbia, March 01, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to announce the upgrade of its com... Read More...

Optimi Health Launches E-Commerce Platform Featuring All-Natural Functional Mushroom Supplements

Optimi Health Corp.--B.C. company brings highest quality fruiting body mushroom formulations to the Canadian nutraceutical marketVANCOUVER, British Columbia., Feb. 22, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and... Read More...

UPDATE – Optimi Health Launches E-Commerce Platform Featuring All-Natural Functional Mushroom Supplements

VANCOUVER, British Columbia., Feb. 22, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to announce the official launch of its line of functi... Read More...

Optimi Health Approved to Supply Psilocybin Under Health Canada’s Special Access Program

Optimi Health Corp.VANCOUVER, British Columbia, Feb. 16, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to report that Health Canada has ad... Read More...

Optimi Health Dealer’s License Granted by Health Canada

Optimi Health to become a global leader in all-natural psilocybin productionVANCOUVER, British Columbia, Feb. 07, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellne... Read More...

Optimi Health Submits Natural Psilocybin Combined Drug Delivery and Extraction Formulations for Provisional Patent

VANCOUVER, British Columbia, Jan. 18, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to announce a second provisional patent for a propriet... Read More...

Optimi Health Provides Dealer License Update and Comments on Health Canada’s Amendments to the Special Access Program (SAP)

VANCOUVER, British Columbia, Jan. 05, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to report the successful completion of the Health Cana... Read More...

Optimi Health Receives Dealers License Inspection and Introduces Quality Assurance Department

VANCOUVER, British Columbia, Dec. 21, 2021 -- Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional as well as novel psychedelic compounds focused on the health and wellness sector, is pleased to announce a facility inspection under ... Read More...

Optimi Health Engages Expert Management Consultancy to Drive Corporate Visibility

VANCOUVER, British Columbia, Nov. 03, 2021 -- Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional as well as novel psychedelic compounds focused on the health and wellness sector, is pleased to announce the engagement of management... Read More...

Optimi Health Clears Final Base Shelf Prospectus

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVANCOUVER, British Columbia, Aug. 18, 2021 -- Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to ... Read More...

Optimi Health Strengthens Clinical and Regulatory Expertise

VANCOUVER, British Columbia, July 27, 2021 -- Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), as part of its strategic aim to fully investigate the science of mushrooms, is pleased to announce the engagement of industry veteran Mr. John Simon to facilitate regulatory submissions and planning relevant t... Read More...

Optimi Health Joins First Psychedelic Exchange Traded Fund

VANCOUVER, British Columbia, July 13, 2021 -- Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a vertically integrated developer of mushroom products is pleased to announce its inclusion in the first psychedelics Exchange Traded Fund (“ETF”) (NEO: PSYK). The ETF began trading on the Neo Exchange as of J... Read More...

Optimi Health Initiates Pathway to Nasdaq Listing

VANCOUVER, British Columbia, July 07, 2021 -- Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a vertically integrated developer of mushroom products announced today that it has engaged the consulting services of Donohoe Advisory Associates LLC (“Donohoe Advisory”) to explore strategies to advance towar... Read More...